Triptorelin: what the evidence shows, status and safety

Summary

Triptorelin is a synthetic copy of a natural hormone that controls the sex glands, changed at a single position. It is a prescription medicine in every market checked, and unusual: given once it switches the pituitary gland on, given continuously it switches it off. The best-documented long-term harm is bone loss, and several of its uses rest on studies without a placebo group.

Key findings at a glance

• One substance, two opposite effects. A single dose makes the pituitary release hormones; continuous exposure from a depot first causes a surge, then shuts the gland down ^[1], ^[2].
• Prescription-only in all seven markets checked. Germany names it in its prescription ordinance without exception, Australia in schedule 4 ^[3], ^[4].
• Bone loss is the best-documented long-term harm. In 29 men treated for a paraphilic disorder, with no cancer involved, bone density scores fell by about half a standard deviation over 6.6 years ^[5].
• The sports ban applies to men only. The 2026 prohibited list covers it under a heading reading "in males"; German law knows no such limit ^[6], ^[7].
• The post-cycle story does not survive checking. Of 601 seized samples analysed by a Polish state laboratory, triptorelin appeared in none of the 63 declared as post-cycle products ^[8].

What it is

Triptorelin is a decapeptide: a chain of ten amino acids copying gonadotropin-releasing hormone, the signal the brain sends to the pituitary gland to keep the sex glands running, with one building block swapped ^[9], ^[1].

That swap is the whole invention. In position six the natural glycine is replaced by D-tryptophan, a mirror-image amino acid that the enzymes cutting the hormone apart no longer recognise, so the molecule survives far longer. It was first made in the 1970s in Andrew Schally's laboratory as D-Trp6-LHRH; the depot forms came later, from three European manufacturers, which is why it carries so many codes and trade names ^[2], ^[9].

The trade names differ by market: Trelstar and Triptodur in the United States, Decapeptyl in Britain, Germany, Switzerland, Canada, Australia and France, Gonapeptyl Depot in Britain and Germany, Diphereline in Australia, Pamorelin in Switzerland, Salvacyl in Britain and Switzerland ^[10], ^[11], ^[12], ^[13], ^[14]. One name belongs on that list for a different reason: Ovugel is a veterinary gel for synchronising ovulation in pigs, and it turns up in register searches beside the human products ^[15].

Quick facts

How it works

The substance binds to one receptor, on the hormone-producing cells of the pituitary gland. What it does there depends on the timing of the signal, not on the molecule ^[1], ^[2].

• The natural system works in pulses. The brain releases its hormone in bursts, roughly every ninety minutes; only that rhythm keeps the pituitary responsive ^[2].
• A single dose stimulates. The pituitary releases luteinising hormone and follicle-stimulating hormone, and testosterone or oestradiol rises with them; the label calls the substance "100-fold more active than native GnRH in stimulating luteinizing hormone release" ^[1].
• Continuous exposure does the opposite. A depot holds the receptor occupied without pause; the cells withdraw their receptors and hormone production falls to very low levels ^[1], ^[2].
• The switch has a delay. The label is plain: "Following the first administration, there is a transient surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and estradiol." Levels rise before they fall ^[1].

The suppression it produces is a reversible medical castration, though how fast and how completely the system recovers is not documented with reliable figures in the sources used here ^[18]. Antagonists such as degarelix and relugolix block the same receptor instead of switching it on, so they produce no initial surge ^[1]. The delivery system matters as much as the molecule: the depot forms embed the substance in microparticles of a slowly degrading polymer, poly(lactide-co-glycolide), released over one to six months. Raw powder sold as a chemical is therefore a different thing pharmacologically, because that carrier is missing ^[12], ^[1].

What the studies found

The research field is large and old: 297 studies are registered ^[19].

The same 100 entries correct a common shortcut: 23 name prostate carcinoma, 18 infertility and a further 14 related reproductive conditions ^[19].

Endometriosis

Network meta-analysis Sixteen randomised trials with 1,605 women and ten medicines were compared after fertility-preserving surgery. For triptorelin, no significant reduction in recurrence was reported ^[20].

Phase 3 RCT A later Chinese trial randomised 300 women aged 18 to 45 across 24 centres, 150 per group, and found no difference in oestradiol suppression at week 12 between two formulations of the same substance. There was no placebo group, so it shows that two preparations behave alike, not that either beats no treatment ^[21].

Randomised trial Of 302 women enrolled after surgery for ovarian endometriosis, 280 were analysed: 138 on triptorelin, 142 on leuprorelin. Anxiety, depression, vaginal dryness, headache and acne were significantly more common under triptorelin, and the hormones pointed the same way: after 21 days the groups differed in FSH (p = 0.003), LH (p = 0.026) and oestradiol (p = 0.002); at six weeks FSH (p = 0.021) and oestradiol (p = 0.033) were still higher under leuprorelin, while the LH difference had gone (p = 0.917). Leuprorelin, the authors concluded, lowered the system more gently ^[22].

Uterine fibroids

Prescrire reviews The independent French drug bulletin assessed the evidence for use before surgery twice. Its 2001 verdict was "no proven value", and on triptorelin: "In the absence of comparative double-blind trials, the observed effects of triptorelin on the choice of surgical technique are uninterpretable" ^[23]. The 2014 reassessment held — it is not established that these drugs lower the need for transfusion or make the operation easier, and the balance of longer use was judged unfavourable ^[24]. A three-centre trial in 125 women, 63 on triptorelin and 62 on leuprorelin, found no significant difference; adverse events occurred in 71 per cent of both groups ^[25].

Central precocious puberty in children

Single-arm trials The American approval for children rests on one open study in 44 children aged two to nine, 88.6 per cent girls, without a control group ^[26]. A Chinese trial followed 66 children, 93.9 per cent girls, median age 8.0 years, range five to nine, equally open and uncontrolled; 13 (19.7 per cent) had 22 drug-related adverse events, none of grade 3 or higher ^[27].

Adult height, the open question

Registry study Spanish paediatric endocrinologists put the problem in their own words: these medicines "are the treatment of choice for idiopathic CPP, but their benefit on height gain is unclear" ^[28].

Retrospective cohorts An independent group followed 12 boys and 81 girls. Among girls with the idiopathic form, final adult height was comparable in the 48 treated and the 15 untreated, 161.5 cm against 161.0 cm, although the untreated reached menarche 2.5 years earlier; in 38 per cent, bone age kept advancing during treatment ^[29]. An older study of 44 children on a different agent of this class showed why such forecasts mislead: the prediction at the end of treatment overestimated the height actually reached ^[30]. In 69 overweight and obese girls, 21 on triptorelin and 48 on leuprolide, there was no significant difference ^[31].

What is still unknown

Several gaps run through all of this. No reliable half-life figure for the free substance could be taken from the primary sources; only a relative one, that the biological half-life after injection under the skin is roughly ten times longer than after infusion into a vein ^[2]. The suppression is called reversible, but no dependable figures on the speed or completeness of recovery were found ^[18]. No comparison against placebo appears in the sources used here: every randomised comparison runs against another drug or another formulation of the same one ^[20], ^[21]. For puberty blocking in gender dysphoria, long-term data are missing ^[32], ^[33]. And every safety dataset comes from settings with laboratory monitoring and bone density measurement; there is none for use outside them.

Side effects and safety

Most of what is known comes from approved product information and cohorts followed for years. Two themes dominate: the surge at the start, and what long-term loss of sex hormones does to the skeleton and circulation ^[1], ^[18].

• In men. Hot flushes are the most frequent effect, at 58.6 to 73.0 per cent depending on the formulation, followed by skeletal pain 12.1 to 13.2 per cent, erectile dysfunction 2.3 to 10.0 per cent, testicular shrinkage 7.5 per cent, headache 5.0 to 7.5 per cent, leg swelling up to 6.3 per cent, leg pain up to 5.2 per cent and injection-site pain 3.6 to 4.0 per cent ^[1].
• In children. Among the 44 children in the paediatric study, 45 per cent had injection-site reactions, mostly pain; nasopharyngitis and headache followed at 13.6 per cent each, gastroenteritis and cough at 6.8 per cent each, menstrual bleeding in 7.7 per cent of girls ^[26].
• In women. Hormone-withdrawal symptoms dominate: in the fibroid trial, nine of 63 women on triptorelin and six of 62 on the comparator needed extra hormone treatment for severe menopausal complaints ^[25].
• Severe osteoporosis is a contraindication, alongside known hypersensitivity to the substance or to related compounds, and pregnancy ^[18], ^[1], ^[26].

Bone loss

Retrospective cohort The clearest evidence comes from a group with no cancer: 53 men treated for a paraphilic disorder, mean age 39.1 years, range 17.5 to 74.6. In the 29 given a GnRH agonist, bone density scores fell significantly at every site measured over 6.6 ± 4.4 years ^[5].

In 13 men of the same study given an androgen-receptor blocker instead, the fall over 6.0 ± 5.3 years was smaller: lumbar spine −0.39 ± 0.17 (p = 0.046), femoral neck −0.34 ± 0.09 (p = 0.002), total femur −0.33 ± 0.12 (p = 0.014) ^[5]. Product information treats this as known: one British text states that long-term suppression of testosterone "is associated with increased risk of bone loss and may lead to osteoporosis and increased risk of bone fracture", and requires a bone density measurement beforehand and enough calcium and vitamin D during treatment ^[18].

Prospective cohort In 121 adolescents given puberty blockers, bone density scores fell in every group studied over two years. In 78 followed for three further years on gender-affirming hormones they recovered in transgender boys but stayed below average in transgender girls. Whether that raises fracture risk is unclear, and the study examined the drug class, not triptorelin alone ^[34].

Other documented risks

• Heart, circulation and metabolism. The American label warns that an "increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported"; it also names raised blood sugar, diabetes, raised blood lipids and fatty liver, and requires periodic checks of lipids, glucose and HbA1c ^[1].
• Heart rhythm and seizures. The loss of sex hormones may lengthen the QT interval, and the label records that convulsions have occurred under medicines of this class ^[1].
• Severe skin and allergic reactions. Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome, acute generalised exanthematous pustulosis, anaphylactic shock and angioedema have all been reported ^[1].
• In children specifically. Psychiatric events, described in the label as crying, irritability, impatience, anger and aggression; raised pressure inside the skull; and a temporary increase in the signs of puberty, including vaginal bleeding, during the first weeks — the same initial surge in a young body ^[26].

Pharmacovigilance An analysis of American adverse-event reports on five long-acting agents of this class, from January 2004 to September 2023, found substantial differences between them; the risk of medically important events was markedly lower in people under 18 than in adults ^[35]. One finding runs the other way: a curated review of drug-induced liver injury notes that these agents raise liver enzymes temporarily, but that "none have been convincingly implicated in causing clinically significant liver injury with jaundice" ^[36].

Why this page lists no doses

This page gives no amounts of triptorelin in any unit, and no injection intervals. The substance is a prescription-only medicine in every market checked, and amounts belong in a prescription and in the approved product information ^[3], ^[16]. The delivery form makes that stricter rather than looser: the main preparations are depots, and a wrong amount cannot be stopped, cannot be reversed and keeps acting for the whole release period ^[12].

Development and approval status

Triptorelin is an established medicine rather than an investigational one: all seven registers checked on 17 September 2026 returned an authorised, prescription-only product ^[16], ^[11], ^[12].

The authorised fields of use differ by market. Across the registers checked they comprise advanced prostate carcinoma, endometriosis, uterine fibroids before an operation, central precocious puberty in children, and down-regulation in reproductive medicine ^[1], ^[26], ^[37], ^[12]. One further field stands under a separate authorisation of its own, reading in the approved text "the reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations" ^[18]. One Swiss authorisation carries four of those fields at once ^[12].

The European row invites a wrong conclusion. There is no centralised European authorisation, and a search of the union register returns nothing — but the same search returns nothing for goserelin either ^[38]. The reason is age, not absence: medicines of this class were authorised nationally, long before the centralised procedure existed, and national evidence was found for Britain, Germany and Switzerland ^[3], ^[13], ^[12].

Two register facts round out the picture: the substance is registered in the United States as a bulk ingredient by a named manufacturer, the lawful raw-material channel for finished medicines ^[10], and it appears in none of the three categories of the American list of substances nominated for pharmacy compounding ^[39]. The wider framework is under are peptides legal and FDA-approved peptides.

Anti-doping

Triptorelin is prohibited at all times, in and out of competition, for male athletes. The 2026 prohibited list names it in section S2.2.1, and everything in that class counts as a non-specified substance, the stricter category ^[6].

The limitation sits in the heading, which reads "Testosterone-stimulating peptides in males"; the entry itself lists gonadotrophin-releasing hormone and its agonist analogues, triptorelin among them. For female athletes, this position establishes no ban ^[6].

German law is written differently, and the difference matters. The annex to the German anti-doping act names triptorelin in section II number 2.1 with no reference to sex, and its closing sentence extends the list to salts, esters and derivatives ^[7].

Both statements are correct in their own legal sphere, and a sentence merging them is wrong either way. Australia adds a third layer, listing the substance by name in schedule 4 of its poisons standard ^[4]. It is also detectable: five metabolites have been identified in human urine by mass spectrometry, one of them first described in 2023 ^[40], ^[41]. More on this class at peptides banned in sport.

Compared with related peptides

The agonists differ less in what they do than in how steeply they do it, and against gonadorelin the contrast is one of duration: the natural hormone is broken down within minutes ^[22], ^[2]. The last row is the real dividing line, since antagonists never switch the receptor on at all ^[1]. One further comparison belongs here because of how the substance is traded — hCG acts on a different receptor, and is one of the agents that reviews of steroid-induced hypogonadism actually discuss ^[42].

Common misconceptions

• "It suppresses hormones, full stop." Only when given continuously. A single dose stimulates, which is precisely what the diagnostic stimulation test uses ^[1], ^[43].
• "All agents of this class are interchangeable." Not shown. In 280 women, side effects were significantly more frequent under triptorelin than under leuprorelin, and a pharmacovigilance analysis found substantial profile differences across five agents ^[22], ^[35].
• "It is not approved in Europe." The central register holds no entry for goserelin either: these are old national approvals, granted before the centralised procedure existed ^[38]. Different trade names do not mean different substances, and one carries an authorisation whose field of use lies in psychiatry ^[18].
• "A depot is just a more convenient injection." It is a different risk situation, and nothing about it can be undone ^[12].

The post-cycle claim, checked

The claim circulating in bodybuilding is that triptorelin can restart the body's own hormone production after a course of anabolic steroids. It begins from something true and then jumps. The true part is the stimulation: a single dose does raise luteinising hormone and testosterone, which is why a diagnostic test built on exactly that exists ^[43], although one comparison found the older hCG-based test the better discriminator ^[44]. Proving that a system can be stimulated is not the same as treating it, and four findings stand against the claim.

• No clinical study exists. A targeted literature search for this use returned nothing that examines it ^[42].
• The standard review does not mention the class. It names testosterone replacement, human chorionic gonadotropin and oestrogen-receptor modulators, and reports that it was planned as a meta-analysis but that "no quality studies met the inclusion criteria" ^[42].
• Specialists do not use it. Of more than 100 endocrinologists surveyed, most advised waiting for spontaneous recovery and about 20 per cent prescribed something; this class was not among the options named ^[45].
• It is not in the seized material. A Polish state laboratory analysed 601 samples between January 2020 and August 2024; among the 63 declared as post-cycle products, triptorelin did not appear ^[8].

Pharmacology argues against repeated use as well: continuous occupation of the receptor down-regulates it, so anyone dosing to stimulate, and dosing too often, achieves the opposite ^[1], ^[2]. The same study shows the second hazard — of the samples analysed, 34.9 per cent did not contain the declared active ingredient; 20.6 per cent held no active substance at all, and 14.3 per cent held other, undeclared ones ^[8].

Use in gender-affirming care

Puberty blocking in adolescents with gender dysphoria is an off-label use: it appears as an authorised field of use in none of the seven markets checked, although the Italian national bioethics committee endorsed the practice in 2018 ^[32]. The debate about long-term consequences for bone density, brain development and fertility, and about the capacity of minors to consent, is explicitly open ^[32], ^[33]. Short-term use is regarded as safe in the literature cited here; the long-term effects on bone health and cardiovascular risk are described as unknown ^[33], ^[34].

Frequently asked questions

What is triptorelin?

A synthetic chain of ten amino acids copying gonadotropin-releasing hormone. One building block is replaced by its mirror image, so the body no longer breaks the molecule down there.

Is triptorelin an approved medicine?

Yes, and it has been for decades. All seven registers checked on 17 September 2026 returned authorised, prescription-only products; the authorised fields of use differ by market.

How can triptorelin both raise and lower hormones?

Because the pituitary gland responds to rhythm, not just to the signal. A single dose makes it release its hormones; continuous exposure from a depot removes the rhythm, and production falls.

Is triptorelin banned in sport?

For male athletes, yes, at all times, under section S2.2.1 of the 2026 prohibited list, whose heading reads "in males". German anti-doping law knows no such limitation.

Does triptorelin restart the hormone axis after a steroid cycle?

There is no clinical study showing that it does. In 601 seized samples it did not appear among those declared as post-cycle products, and repeated dosing would suppress rather than stimulate.

What are the main risks of triptorelin?

Bone loss is the best documented: in men treated for years without any cancer involved, bone density scores fell by about half a standard deviation. Product information also warns of cardiovascular and metabolic effects.

Is triptorelin the same as leuprorelin or goserelin?

They belong to the same class, but are not identical. In a randomised comparison of 280 women, anxiety, depression, vaginal dryness, headache and acne were significantly more frequent under triptorelin.

Why does this page list no triptorelin doses?

Because it is a prescription-only medicine in every market checked, and amounts belong in a prescription and in the approved product information. A depot injection, once given, cannot be reversed.

Is triptorelin used in gender-affirming care?

It is used off-label to delay puberty in adolescents with gender dysphoria, and is an authorised field of use in no market checked. Long-term data on bone, brain and fertility are missing.

Can triptorelin be detected in doping tests?

Yes. Five metabolites have been identified in human urine by mass spectrometry, one first described in 2023, and detection methods for doping control have been published.

Cite this page

Every register behind the status table was queried on 17 September 2026. Two things remain open: no reliable half-life figure for the free substance exists in the sources used, and the German authorisation numbers could not be retrieved from an official register.

myPeptides Research & Editing. (2026). Triptorelin: what the evidence shows, status and safety. Version 1.0, 17 September 2026. myPeptides Peptide Register. Retrieved from https://mypep.app/peptides/triptorelin

How pages in this register are compiled and graded is described under methodology; the full register is at peptides.

Last verified: 17 September 2026. Next review: on any change to the prohibited list, on any new authorisation or withdrawal in the seven markets checked, or on publication of reliable data on recovery of the hormone axis.